Home > Press > Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference
Arrowhead Research to Present at the 13th Annual BIO CEO & Investor Conference
Pasadena, CA | Posted on February 9th, 2011
Arrowhead Research Corporation (NASDAQ: ARWR), a focused nanomedicine holding company, today announced that Dr. Christopher Anzalone, Chief Executive Officer, will present at the 13th Annual BIO CEO & Investor Conference at 8:00 a.m. Eastern time on Monday, February 14, 2011 at the Waldorf-Astoria Hotel in New York City, New York. Dr. Anzalone will be discussing recent Company developments and its opportunities in nanomedicine.
The presentation will be webcast live and can be accessed by visiting the Company's website at www.arrowheadresearch.com. A replay of the presentation will be archived on the Arrowhead website for 90 days.
####
About Arrowhead Research Corporation
Arrowhead Research Corporation (NASDAQ: ARWR) is a nanomedicine company developing innovative therapeutic products at the interface of biology and nanoengineering to cure disease and improve human health. Arrowhead addresses its target markets through focused subsidiaries, which include: Calando Pharmaceuticals, a leader in delivering small RNAs for gene silencing; Ablaris Therapeutics, an anti-obesity therapeutics company; and Nanotope, a regenerative medicine company.
For more information, please click here
Copyright © Arrowhead Research Corporation
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
News and information
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Nanomedicine
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Announcements
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
New Method to Synthesize Zinc Oxide Nanoparticles with High Catalytic Activity June 18th, 2013
Production of Polyaniline Biosensors Modified with Conductive Polymer Composites June 18th, 2013
Events/Classes
Research and industry frontrunners gather in Dublin at the EuroNanoForum, Europe’s largest nanotechnology conference June 18th, 2013
Discover the ‘Nanostructure Advantage’ at ECerS 2013, Booth 5: Innovnano presents nanostructured powders for high performance ceramics June 17th, 2013
SEMATECH to Address Critical Supply Chain Challenges and Present Latest Technology Advances at SEMICON West 2013 June 17th, 2013
Imec shows multiple enhancement options for next-generation FinFETs: Leading nano-electronics R&D center addresses key challenges of Germanium finFET technology at VLSI 2013 June 14th, 2013